Table 1.
League table
| Upadacitinib 30 mg | Upadacitinib 15 mg | Dupilumab 300 mg q2w | Dupilumab 300 mg weekly | Dupilumab 300 mg q4w | Abrocitinib 200 mg | Abrocitinib 100 mg | Abrocitinib 10 - 30mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Upadacitinib 30 mg | 0.59 (0.42, 0.84) | 0.13 (0.04, 0.45) | 0.16 (0.06, 0.45) | 0.17 (0.02, 1.48) | 0.78 (0.23, 2.61) | 0.35 (0.09, 1.34) | 1.13 (0.12, 11.04) | 0.23 (0.10, 0.53) |
| 1.68 (1.19, 2.38) | Upadacitinib 15 mg | 0.22 (0.06, 0.78) | 0.28 (0.10, 0.78) | 0.28 (0.03, 2.53) | 1.31 (0.38, 4.49) | 0.59 (0.15, 2.30) | 1.91 (0.19, 18.80) | 0.39 (0.17, 0.92) |
| 7.54 (2.21, 25.68) | 4.48 (1.29, 15.57) | Dupilumab 300 mg q2w | 1.24 (0.36, 4.23) | 1.26 (0.14, 11.05) | 5.87 (2.08, 16.51) | 2.62 (0.76, 9.03) | 8.56 (0.91, 80.61) | 1.76 (0.67, 4.59) |
| 6.09 (2.24, 16.52) | 3.61 (1.28, 10.18) | 0.81 (0.24, 2.75) | Dupilumab 300 mg weekly | 1.01 (0.12, 8.87) | 4.74 (1.34, 16.79) | 2.12 (0.52, 8.61) | 6.91 (0.69, 69.66) | 1.42 (0.56, 3.62) |
| 6.01 (0.67, 53.48) | 3.57 (0.40, 32.14) | 0.80 (0.09, 7.01) | 0.99 (0.11, 8.63) | Dupilumab 300 mg q4w | 4.67 (0.51, 42.85) | 2.09 (0.21, 20.82) | 6.82 (0.36, 129.48) | 1.40 (0.18, 10.97) |
| 1.29 (0.38, 4.32) | 0.76 (0.22, 2.61) | 0.17 (0.06, 0.48) | 0.21 (0.06, 0.75) | 0.21 (0.02, 1.96) | Abrocitinib 200 mg | 0.45 (0.19, 1.04) | 1.46 (0.18, 11.81) | 0.30 (0.12, 0.75) |
| 2.87 (0.75, 11.07) | 1.71 (0.43, 6.69) | 0.38 (0.11, 1.31) | 0.47 (0.12, 1.92) | 0.48 (0.05, 4.76) | 2.23 (0.96, 5.20) | Abrocitinib 100 mg | 3.26 (0.39, 27.12) | 0.67 (0.23, 1.98) |
| 0.88 (0.09, 8.57) | 0.52 (0.05, 5.14) | 0.12 (0.01, 1.10) | 0.14 (0.01, 1.46) | 0.15 (0.01, 2.79) | 0.69 (0.08, 5.55) | 0.31 (0.04, 2.55) | Abrocitinib 10 - 30mg | 0.21 (0.02, 1.72) |
| 4.29 (1.89, 9.74) | 2.55 (1.09, 5.95) | 0.57 (0.22, 1.49) | 0.71 (0.28, 1.80) | 0.71 (0.09, 5.60) | 3.34 (1.34, 8.31) | 1.49 (0.50, 4.42) | 4.87 (0.58, 40.90) | Placebo |
League table showing the comparative risk of HZ included for different interventions in this network meta-analysis. Upadacitinib 15 mg and 30 mg caused a significant increase in HZ when compared to various frequencies of dupilumab and placebo. Abrocitinib 200 mg caused a significant increase in HZ when compared to placebo. Bold text represents statistically significant comparisons, while non-bold boxes indicate non-statistically significant comparisons.